Surprisingly, we founded the 1779 upregulated DEGs in ICT-treated tumors were mainly enriched in immune system process, inflammatory response, NF−kappaB signaling and innate immune response, which indicated that ICT could target TME regulation immune pathway in murine tumor models (Figure 7A). The gene discussed is NFKB1; the disease is neoplasm.